Prophylaxis in Patients with Von Willebrand Disease: Expert Perspectives and Shared Experiences
Please use the box in the top-right corner of the screen to login or register.
Release Date: September 27, 2022
Expiration Date: September 27, 2023
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
Von Willebrand Disease (VWD) is the most common inherited bleeding disorder in the United States. Despite this, however, many healthcare professionals lack the knowledge required to diagnose or treat VWD. This activity addresses the importance of long-term prophylaxis in VWD on guideline recommendations for long-term prophylaxis, and on emerging data regarding novel agents for prophylaxis in this disease. This program will conclude with case discussions designed to improve the awareness concerning symptoms of VWD and diagnostic assessments in order to better manage and treat the patients in your practice.
This activity is intended for hematologists, primary care physicians, pediatricians, obstetricians, gynecologists, physician assistants, nurse practitioners and other healthcare professionals who provide care for patients with von Willebrand Disease (VWD).
Upon completion of this educational activity, participants should be able to:
- Outline recent guidelines concerning the use of short- and long-term prophylaxis in patients with von Willebrand Disease (VWD)
- Identify patient and disease characteristics that suggests a patient with von Willebrand Disease will benefit from long-term prophylaxis
- Summarize the safety and efficacy data from recent and ongoing trials investigating novel prophylaxis agents for VWD
- Outline factors that must be considered when identifying therapeutic strategies, doses and regimens for prophylaxis in patients with VWD
The Current Standard of Care in Von Willebrand Disease; Meeting Today’s Challenges – Robert F. Sidonio, Jr., MD
VWD and Prophylaxis: Applying Guidelines to Best Practice – Angela C. Weyand, MD
Therapeutic Strategies in VWD: A Closer Look at the Use of Prophylaxis Treatment – Miguel A. Escobar, MD
Instructions for Participation and Credit
This activity is eligible for credit through September 27, 2023. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation.
Robert Sidonio, Jr., MD
Hemostasis and Thrombosis
Dr. Robert Sidonio, Jr. received his medical degree from the University of Alabama (UAB) medical school. He completed his pediatric residency at the University of Louisville, and his fellowship at the University of Pittsburgh, where he also obtained his masters’ in clinical investigation. Dr. Sidonio has been the Associate Director of Hemostasis and Thrombosis at Emory University in Atlanta, Georgia since 2014.
Dr. Sidonio’s clinical and research interest is in investigating the bleeding phenotype and genotype of women with hemophilia carriage and low von Willebrand factor (VWF). He is also the co-creator of the ‘Atlanta Protocol’ which combines emicizumab and Factor VIII (FVIII) for immune tolerance induction (ITI). He is a co-principal investigator of the Hemophilia of Georgia (HOG)Von Willebrand disease (VWD) project focused on characterization of children with low VWF in Georgia. He is also the principal investigator for the Emi PUP and Nuwiq ITI trial, MOTIVATE study, ATHN 9 study (severe VWD).
Miguel A. Escobar, MD
Professor of Medicine and Pediatrics
Director, Clinical Research Center
McGovern Medical School
The University of Texas Health Science Center
Dr. Miguel Escobar earned his medical degree at Universidad Libre De Colombia in Bogotá. He completed his internship and residency at the University of Connecticut and a fellowship at the University of North Carolina at Chapel Hill. Dr. Escobar is Director of the Clinical Research Center and Professor of Medicine and Pediatrics at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth). He also serves as Medical Director of the Gulf States Hemophilia and Thrombophilia Center in Houston.
Dr. Escobar is board certified in internal medicine and hematology. He specializes in rare blood disorders, and his primary clinical interests include adult bleeding and clotting disorders, hemophilia, von Willebrand disease and deep vein thrombosis. His research interests involve bleeding and hemostasis in patients with hemophilia and other congenital and acquired bleeding disorders.
Angela C. Weyand, MD
Clinical Assistant Professor
Pediatrics - Hematology/Oncology
University of Michigan, Ann Arbor
Ann Arbor, Michigan
Dr. Angela Weyand received her medical degree from the University of Michigan Medical School, Ann Arbor. She completed her pediatrics residency at the University of Washington/Seattle Children's Hospital and returned to the University of Michigan for her pediatric hematology and oncology fellowship. She is Clinical Assistant Professor, Pediatrics - Hematology/Oncology at the University of Michigan, Ann Arbor.
Dr. Weyand is American Board of Pediatrics certified in general pediatrics and pediatric hematology and oncology. She is Co-Director, of the Combined Hematology and Gynecology Clinic, Associate Fellowship Director of Advanced Coagulation and Pediatric Hematology and Oncology, as well as Associate Director of the Hemophilia Treatment Center at the University of Michigan, Ann Arbor. Her clinical interested is in young women and girls with bleeding or clotting disorders and she is the co-director of a combined hematology/gynecology program serving this population. Her research interests are in genetic modifiers of hemostasis and thrombosis, women and girls with bleeding disorders, hormone provoked thrombosis, and von Willebrand disease.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 22-12-156
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Dr. Robert Sidonio, Jr. has relevant financial relationships related to consulting from Bayer AG, Genentech, Inc., Grifols S.A., Guardian Therapeutics, Novo Nordisk A/S, Octapharma USA, Inc., Sanofi, Sobi, and Takeda Oncology, as well as investigator sponsored studies from Genentech, Octapharma, and Takeda.
Dr. Miguel Escobar has relevant financial relationships related to advisory activities from CSL Behring, Genentech - A Member of the Roche Group, HEMA Biologics, LLC, LFB Biopharmaceuticals Limited, Novo Nordisk A/S, Pfizer Inc., Sanofi, Takeda Oncology, and uniQure N.V., as well as consulting from HEMA Biologics and LFB. He is on the speakers’ bureau for Bayer AG, BioMarin Pharmaceutical Inc., and Kedrion, and has received research grant(s) from Genentech - A Member of the Roche Group, Novo Nordisk A/S, Sanofi, Takeda, and uniQure.
Dr. Angela Weyand has relevant financial relationships related to consulting from Bayer AG, Genentech - A Member of the Roche Group, Sanofi, and Takeda Oncology. She has received research grant(s) from Novo Nordisk A/S, Pfizer Inc., Sanofi, and Takeda.
All of the relevant financial relationships listed for these individuals have been mitigated.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
©2022 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Please use the box in the top-right corner of the screen to login or register.